ROBIN FOUQUET: Open Payments
NPI 1114536703 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 8 payments from 7 companies in 2025. Trend: 2023 $120 · 2024 $16 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 2 | $151 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 1 | $115 |
| PFIZER INC. | 1 | $19 |
| Organon LLC | 1 | $18 |
| Exact Sciences Corporation | 1 | $16 |
Products named: Epclusa, REXULTI, CAPLYTA, AIRSUPRA, PAXLOVID, NEXPLANON, Cologuard Collection Kit.
Industry payments across LA — which companies pay providers there.
